Maze Therapeutics (NASDAQ:MAZE) Hits New 52-Week Low – Here’s Why

Maze Therapeutics, Inc. (NASDAQ:MAZE)’s share price hit a new 52-week low during mid-day trading on Friday . The company traded as low as $22.44 and last traded at $22.2150, with a volume of 78037 shares trading hands. The stock had previously closed at $23.44.

Wall Street Analysts Forecast Growth

MAZE has been the subject of several research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Maze Therapeutics in a research note on Wednesday, June 24th. Wall Street Zen cut shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. BTIG Research reaffirmed a “buy” rating and issued a $46.00 target price on shares of Maze Therapeutics in a research report on Wednesday, August 12th. Finally, TD Cowen upgraded shares of Maze Therapeutics to a “strong-buy” rating in a research note on Monday, August 24th. Three investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $66.00.

Maze Therapeutics Price Performance

The business has a fifty day moving average of $27.53 and a two-hundred day moving average of $29.74. The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.31 and a current ratio of 18.31. The firm has a market capitalization of $1.23 billion, a price-to-earnings ratio of -8.81 and a beta of 2.17.

Maze Therapeutics (NASDAQ:MAZE) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.76) EPS for the quarter, hitting analysts’ consensus estimates of ($0.76). As a group, research analysts predict that Maze Therapeutics, Inc. will post -2.72 EPS for the current fiscal year.

Insider Buying and Selling at Maze Therapeutics

In other news, CEO Jason V. Coloma sold 34,501 shares of the stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $26.29, for a total transaction of $907,031.29. Following the transaction, the chief executive officer owned 18,151 shares in the company, valued at approximately $477,189.79. This trade represents a 65.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Harold Bernstein sold 16,142 shares of Maze Therapeutics stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $27.61, for a total value of $445,680.62. Following the sale, the chief marketing officer directly owned 16,142 shares of the company’s stock, valued at approximately $445,680.62. The trade was a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 219,317 shares of company stock valued at $5,989,040 in the last three months. 5.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Maze Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Royal Bank of Canada increased its position in shares of Maze Therapeutics by 214.1% in the first quarter. Royal Bank of Canada now owns 2,029 shares of the company’s stock worth $61,000 after purchasing an additional 1,383 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in shares of Maze Therapeutics during the 2nd quarter worth approximately $48,000. Quantbot Technologies LP bought a new position in Maze Therapeutics in the second quarter valued at approximately $80,000. Caitong International Asset Management Co. Ltd acquired a new position in Maze Therapeutics during the fourth quarter valued at approximately $145,000. Finally, IFP Advisors Inc acquired a new stake in shares of Maze Therapeutics in the 4th quarter valued at $146,000.

About Maze Therapeutics

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetically driven diseases. The company combines human genetics, functional genomics and drug discovery technologies through its Maze Compass platform to identify disease mechanisms and develop therapies designed to address the underlying causes of disease.

Maze’s lead program, MZE001, is an oral small-molecule inhibitor of glycogen synthase being developed for Pompe disease, a rare inherited disorder in which glycogen accumulates in muscles and other tissues.